HomeBUSINESS
BUSINESS

As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll
(Jul.13.2018)

By Reiji Anasako

Despite a heated development race underway for biosimilar versions of big-name biologics, follow-on products are not making as smooth a headway as generic counterparts. While biosimilars of eight APIs currently available in Japan have yielded mixed performances, Eli Lilly’s Lantus (recombinant insulin glargine) follow-on appears to be gaining traction, outstripping its originator in the basal insulin market ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 20.

News Calendar